Skip to main content
RKLBFYI

Intelligence Hub

Market analytics and operational performance indicators

Last Updated: 14 minutes ago
Back to Filings
FORM 144
AI

144 - May 28, 2025

Filed May 28, 2025
·
0001950047-25-003546

Rocket Lab officer Arjun Kampani files Form 144 to sell 5,277 shares under 10b5-1 plan.

Brief

This Form 144 filing discloses Rocket Lab officer Arjun Kampani's intent to sell 5,277 common shares acquired via RSUs on 03/01/2025, with aggregate value of $151,766.52, approximately on 05/28/2025. The sale relies on a Rule 10b5-1 trading plan adopted on 12/12/2024. Recent sales by Kampani in March 2025 totaled 34,113 shares for ~$626k, indicating routine vesting liquidity.

Detailed Brief

Form 144 is a notice of proposed sale of restricted securities under Rule 144 by Arjun Kampani, an officer of Rocket Lab USA Inc. (RKLB). He plans to sell 5,277 common shares through Morgan Stanley, valued at $151,766.52 based on market price, with ~461 million shares outstanding. Shares were acquired on 03/01/2025 from restricted stock units (RSUs) issued by the company. The transaction follows a pre-established Rule 10b5-1 plan adopted on 12/12/2024, which allows insiders to sell without market timing concerns. Kampani discloses prior sales within the past 3 months: 28,836 shares on 03/14/2025 for $524,275.97 and 5,277 shares on 03/17/2025 for $102,124.20. He certifies no undisclosed material adverse information about Rocket Lab's operations. This is a standard disclosure for executive compensation vesting in the space launch sector, where RSU sales fund tax obligations.

Key Telemetry

  • Arjun Kampani (officer) to sell 5,277 common shares (~$151.8k) on ~05/28/2025 via 10b5-1 plan (adopted 12/12/2024).
  • Shares from RSUs vested 03/01/2025.
  • Prior 3-month sales: 28,836 shares (03/14/2025, $524k); 5,277 shares (03/17/2025, $102k).
  • ~461M shares outstanding; negligible volume.
  • No material adverse info per certification.

Impact Vector

Routine insider sale under 10b5-1 plan poses minimal near-term impact on RKLB stock, as it's pre-planned and tied to RSU vesting for tax/liquidity needs. Total recent sales (~$778k including proposed) are insignificant vs. market cap (~$20B+ at current prices). Signals no distress; monitor Form 4 confirmations and aggregate insider activity for sentiment. Strategic irrelevance to Rocket Lab's launch cadence or Neutron progress.

Search
Search across missions, customers, news, and SEC filings